Mangafodipir as a cytoprotective adjunct to chemotherapy--a case report.
Yri
Olav Erich
OE
Vig
Jens
J
Hegstad
Elisabeth
E
Hovde
Oistein
O
Pignon
Ingrid
I
Jynge
Per
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015209:Cholangitis, Sclerosing / Q000150:complications; D003082:Colectomy; D003110:Colonic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D003424:Crohn Disease / Q000150:complications; D019610:Cytoprotection; D004492:Edetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D010166:Palliative Care / Q000379:methods; D011732:Pyridoxal Phosphate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid; D002955:Leucovorin; D005472:Fluorouracil